Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Biden adds Ozempic to list for Medicare price negotiationIn one of its last actions, the Biden ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

The phase 3 STEP UP trial enrolled 1407 adults aged 18 years and older with a body mass index of at least 30kg/m2 and without diabetes.

The Centers for Medicare & Medicaid Services announced 15 new drugs it wants to lower the cost for, including popular, but ...

Teva's lawsuit hinges on the claim that two of its drugs with the exact same active ingredient should not both be subject to Medicare drug price negotiations at the same time, according to Merith ...

A shake-up may be brewing in the market for GLP-1 diet drugs Friday, and it's making itself felt all across the field of ...

Leerink Partners maintained a positive outlook on shares of Eli Lilly and Company (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $950.00. The pharmaceutical giant, currently ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

BAGSVAERD, Denmark I January 17, 2025 I Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is ...

Danish diabetes and obesity giant Novo Nordisk today announced headline results from STEP UP, a Phase IIIb trial in the ...

Novo Nordisk said that patients taking a higher dose of its blockbuster Wegovy obesity shot lost more weight than those on a lower dose without experiencing an increase in side-effects, according to a ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...